US5490498A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Partial liquid breathing of fluorocarbons
Assignee: Alliance Pharmaceutical Corp
•
Filing: 1994-09-01
•
Granted: 1996-02-13
•
Expires: 2014-09-01
Abstract
Abstract The present invention includes a method for treating a patient in need of facilitated oxygen delivery through the lungs, additional lung surfactant, removal of material from inside the lung, or inflation of collapsed portions of the lung, comprising the step of introducing into the lung of the patient an effective therapeutic amount of a fluorocarbon liquid, the amount not exceeding the functional residual capacity of the lung of the patient upon exhalation taking into account any positive and expiratory pressure applied to the patient's lung. The method may also comprise the additional step of providing an oxygen-containing breathing gas to the patient while the fluorocarbon liquid is in the lung.
Inventors
- 👤 Nicholas S. Faithfull
- 👤 Jeffry G. Weers
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 00:08
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61K31/135; A61K31/02; A61K31/025; A61K31/035; A61K31/075; A61K31/08; A61K31/66; A61K31/683; A61K31/685; A61K45/00; A61K45/06; A61P; A61P11/00; A61P11/10; A61P31/00; A61P31/04; A61P43/00; A61M; A61M2202/00; A61M2202/04; A61M2202/0468; A61M2202/0476; Y; Y10; Y10S; Y10S128/00; Y10S128/913
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
156 words
A method for treating a patient in need of facilitated oxygen delivery through the lungs, additional lung surfactant, removal of material from the lung, or inflation of collapsed portions of the lung, comprising the steps of: first introducing into the lung of the patient an effective therapeutic amount of a fluorocarbon liquid, said introduced amount being at least about 0.1% and less than 35% of the functional residual capacity of the lung of the patient upon exhalation taking into account any positive or negative end expiratory pressure applied to said patient's lung; and then moving a breathing gas into and out of the patient's lung on top of said introduced fluorocarbon liquid separate and apart from said introducing step, so that said breathing gas physically admixes with and oxygenates said introduced amount of fluorocarbon liquid within the lung, whereby the patient is breathing a gas while the introduced amount of fluorocarbon liquid is in the lung.
Claim 2
Independent Claim
156 words
A method for treating a patient in need of facilitated oxygen delivery through the lungs, additional lung surfactant, removal of material from the lung, or inflation of collapsed portions of the lung, comprising the steps of: first introducing into the lung of the patient an effective therapeutic amount of a fluorocarbon liquid, said introduced amount being at least about 0.1% and less than 35% of the functional residual capacity of the lung of the patient upon exhalation taking into account any positive or negative end expiratory pressure applied to said patient's lung; and then moving a breathing gas into and out of the patient's lung on top of said introduced fluorocarbon liquid separate and apart from said introducing step, so that said breathing gas physically admixes with and oxygenates said introduced amount of fluorocarbon liquid within the lung, whereby the patient is breathing a gas while the introduced amount of fluorocarbon liquid is in the lung.
Claim 3
Dependent Claim
36 words
The method of claim 1, wherein said fluorocarbon liquid contains a pharmacologic agent in particulate form, whereby said agent is suspended in said fluorocarbon liquid and said agent is delivered to the lungs of said patient.
Claim 4
Dependent Claim
12 words
The method of claim 2, wherein said particulate is a solid particulate.
Claim 5
Dependent Claim
25 words
The method of claim 1, wherein the patient is in need of additional lung surfactant and the fluorocarbon liquid has favorable lung surfactant replacement characteristics.
Claim 6
Dependent Claim
27 words
The method of claim 1, wherein the amount of fluorocarbon liquid introduced into the patient's lung is at least about 0.1 ml/kg of said patient's body weight.
Claim 7
Dependent Claim
26 words
The method of claim 1, further comprising the step of facilitating respiration by said patient while said fluorocarbon is in the lung with external ventilation equipment.
Claim 8
Dependent Claim
35 words
The method of claim 1, wherein said patient is in need of removal of material from inside the lung, further comprising the step of removing said fluorocarbon liquid, together with said material, from the lung.
Claim 9
Dependent Claim
36 words
The method of claim 1, wherein said fluorocarbon liquid contains a pharmacologic agent in particulate form, whereby said agent is suspended in said fluorocarbon liquid and said agent is delivered to the lungs of said patient.
Claim 10
Dependent Claim
17 words
The method of claim 8, wherein said pharmacologic agent is a hydrophilic lung surfactant in powdered form.
Claim 11
Dependent Claim
12 words
The method of claim 8, wherein said particulate is a solid particulate.
Claim 12
Dependent Claim
12 words
The method of claim 1, wherein said oxygen-containing breathing gas is oxygen.
Claim 13
Dependent Claim
25 words
The method of claim 1, wherein said introduced amount is between about 0.1% and about 5% of the total inflated lung volume of the patient.
Claim 14
Independent Claim
89 words
A method for facilitating oxygen delivery through the lungs, additional lung surfactant, removal of material from inside the lung, or inflation of collapsed portions of the lung,] comprising the steps of: first introducing into the lung of a patient an effective oxygen delivery-facilitating amount of a liquid fluorocarbon in the form of an aerosol; and then moving a breathing gas into and out of a patient's lung on top of said introduced fluorocarbon aerosol so that said breathing gas oxygenates said introduced amount of fluorocarbon aerosol within the lung.
Claim 15
Independent Claim
89 words
A method for facilitating oxygen delivery through the lungs, additional lung surfactant, removal of material from inside the lung, or inflation of collapsed portions of the lung,] comprising the steps of: first introducing into the lung of a patient an effective oxygen delivery-facilitating amount of a liquid fluorocarbon in the form of an aerosol; and then moving a breathing gas into and out of a patient's lung on top of said introduced fluorocarbon aerosol so that said breathing gas oxygenates said introduced amount of fluorocarbon aerosol within the lung.
Claim 16
Dependent Claim
14 words
The method of claim 13, wherein said fluorocarbon further comprises a dispersed pharmacological agent.
Claim 17
Dependent Claim
13 words
The method of claim 14, wherein said pharmacological agent is in particulate form.
Claim 18
Independent Claim
157 words
A method for treating a patient in need of facilitated oxygen delivery through the lungs, additional lung surfactant, removal of material from inside the lung, or inflation of collapsed portions of the lung, comprising the steps of: first introducing into the lung of the patient an effective therapeutic amount of a fluorocarbon aerosol, said introduced amount being at least about 0.1% and less than 30% of the functional residual capacity of the lung of the patient upon exhalation taking into account any positive or negative end expiratory pressure applied to said patient's lung; and then moving a breathing gas into and out of the patient's lung on top of said introduced fluorocarbon aerosol separate and apart from said introducing step, so that said breathing gas physically admixes with and oxygenates said introduced amount of fluorocarbon aerosol within the lung, whereby the patient is breathing a gas while the introduced amount of fluorocarbon aerosol is in the lung.
Claim 19
Independent Claim
157 words
A method for treating a patient in need of facilitated oxygen delivery through the lungs, additional lung surfactant, removal of material from inside the lung, or inflation of collapsed portions of the lung, comprising the steps of: first introducing into the lung of the patient an effective therapeutic amount of a fluorocarbon aerosol, said introduced amount being at least about 0.1% and less than 30% of the functional residual capacity of the lung of the patient upon exhalation taking into account any positive or negative end expiratory pressure applied to said patient's lung; and then moving a breathing gas into and out of the patient's lung on top of said introduced fluorocarbon aerosol separate and apart from said introducing step, so that said breathing gas physically admixes with and oxygenates said introduced amount of fluorocarbon aerosol within the lung, whereby the patient is breathing a gas while the introduced amount of fluorocarbon aerosol is in the lung.
References Cited (Backward Citations)
US3975512A
Cited
DE2245299A1
Cited
SU858824A1
Cited
SU1143420A1
Cited
US5024995A
Cited
WO1991003267A1
Cited
US5158536A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-02-12 | 1999-08-14 | 2000-02-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-02-12 | 2003-08-14 | 2004-02-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-02-12 | 2007-08-14 | 2008-02-13 | $7700.00 | Window Closed / Lapsed |